Clinical Trial: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104032) titled 'Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)' on July 29.

Brief Summary: The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Primary Central Nervous System Lymphoma

Intervention: DRUG: Tirabrutinib

Administered orally.

DRUG: Rituximab

Administered intravenously (IV).

DR...